Active Ingredient History
CAPOZIDE (captopril and hydrochlorothiazide tablets, USP) for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. The mechanism of action of captopril has not yet been fully elucidated. Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase. Hydrochlorothiazide belongs to thiazide class of diuretics. It reduces blood volume by acting on the kidneys to reduce sodium (Na+) reabsorption in the distal convoluted tubule. CAPOZIDE (captopril and hydrochlorothiazide tablets, USP) is indicated for the treatment of hypertension. The blood pressure lowering effects of captopril and thiazides are approximately additive. Major side effects are: Black, tarry stools; chest pain; chills; cough; fever; painful or difficult urination; shortness of breath; sore throat; sores, ulcers, or white spots on lips or in mouth; swollen glands; unusual bleeding or bruising; unusual tiredness or weakness. It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension. Captopril’s effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 3)
Aging (Phase 2)
Albuminuria (Phase 4)
Angina Pectoris (Phase 4)
Arthritis, Rheumatoid (Phase 1)
Asthma (Phase 1)
Atherosclerosis (Phase 3)
Atrial Fibrillation (Phase 4)
Biological Availability (Phase 1)
Blood Pressure (Phase 4)
Cerebral Small Vessel Diseases (Phase 4)
Chronic Pain (Early Phase 1)
Cognitive Dysfunction (Phase 2)
Coronary Artery Disease (Phase 4)
Critical Illness (Phase 2)
Death, Sudden, Cardiac (Phase 3)
Dent Disease (Phase 2/Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Diabetic Retinopathy (Phase 3)
Diarrhea (Phase 1)
Diuresis (Phase 4)
Drug Interactions (Phase 1)
Edema (Phase 4)
Erectile Dysfunction (Phase 4)
Essential Hypertension (Phase 4)
Fasting (Phase 1)
Fractures, Bone (Phase 3)
Glucose Metabolism Disorders (Phase 4)
Healthy Volunteers (Phase 4)
Heart Arrest (Phase 3)
Heart Disease Risk Factors (Phase 4)
Heart Diseases (Phase 3)
Heart Failure (Phase 4)
Hemodialysis, Home (Phase 4)
Hepatitis B, Chronic (Phase 1)
Hyperhomocysteinemia (Phase 4)
Hyperlipidemias (Phase 2)
Hypernatremia (Phase 2)
Hypertension ()
Hypertension, Pregnancy-Induced (Phase 3)
Hypertrophy, Left Ventricular (Phase 4)
Hyperuricemia (Phase 4)
Hypokalemia (Phase 4)
Hypoparathyroidism (Phase 2)
Insulin Resistance (Phase 1)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Menopause (Phase 4)
Metabolic Diseases (Phase 3)
Metabolic Syndrome (Phase 4)
Myocardial Infarction (Phase 4)
Neoplasms (Phase 3)
Nephrolithiasis (Phase 3)
Nephrotic Syndrome (Phase 4)
Neuritis (Phase 2)
Obesity (Phase 4)
Obesity, Abdominal (Phase 4)
Pharmacogenetics (Phase 4)
Pharmacokinetics (Phase 1)
Pharmacology (Phase 1)
Photosensitivity Disorders (Phase 1)
Polycystic Kidney Diseases (Phase 3)
Prediabetic State (Phase 2)
Pre-Eclampsia (Phase 3)
Prehypertension (Phase 4)
Proteinuria (Phase 4)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Sedentary Behavior (Phase 2)
Sleep Apnea, Obstructive (Phase 4)
Spinal Cord Stimulation (Early Phase 1)
Stroke (Phase 4)
Therapeutic Equivalency (Phase 1)
Vascular Stiffness (Early Phase 1)
Ventricular Remodeling (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
